Evidence map›Paper›PMID 30181811›Full record

ArticleOncotarget2018

Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia.

Veronica Martini, Federica Frezzato, Filippo Severin, Flavia Raggi, Valentina Trimarco, Leonardo Martinello, Rosa Molfetta, Andrea Visentin, Monica Facco, Gianpietro Semenzato and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Veronica MartiniDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
Federica FrezzatoDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
Filippo SeverinDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
Flavia RaggiDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
Valentina TrimarcoDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
Leonardo MartinelloDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
Rosa MolfettaDepartment of Molecular Medicine, University of La Sapienza, Rome, Italy.
Andrea VisentinDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
Monica FaccoDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
Gianpietro SemenzatoDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
Rossella PaoliniDepartment of Molecular Medicine, University of La Sapienza, Rome, Italy.
Livio TrentinDepartment of Medicine, Hematology and Clinical Immunology Branch, University School of Medicine, Padua, Italy.
University of Padua · ITVeneto Institute of Molecular Medicine · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abnormalities of molecules involved in signal transduction pathways are connected to Chronic Lymphocytic Leukemia (CLL) pathogenesis and a critical role has been already ascribed to B-Cell Receptor (BCR)-Lyn axis. E3 ubiquitin ligase c-Cbl, working together with adapter protein CIN85, controls the degradation of protein kinases involved in BCR signaling. To investigate cell homeostasis in CLL, we studied c-Cbl since in normal B cells it is involved in the ubiquitin-dependent Lyn degradation and in the down-regulation of BCR signaling. We found that c-Cbl is overexpressed and not ubiquitinated after BCR engagement. We observed that c-Cbl did not associate to CIN85 in CLL with respect to normal B cells at steady state, nor following BCR engagement. c-Cbl association to Lyn was not detectable in CLL after BCR stimulation, as it happens in normal B cells. In some CLL patients, c-Cbl is constitutively phosphorylated at Y731 and in the same subjects, it associated to regulatory subunit p85 of PI3K. Moreover, c-Cbl is constitutive associated to Cortactin in those CLL patients presenting Cortactin overexpression and bad prognosis. These results support the hypothesis that c-Cbl, rather than E3 ligase activity, could have an adaptor function in turn influencing cell homeostasis in CLL.

Indexed as

CIN85cortactinLynPI3Kp85

Identifiers

PMID30181811
PMCPMC6114956
OpenAlexW2887000187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.